Catalent Reports First Quarter Fiscal Year 2017 Results
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced financial results for the first quarter of fiscal year 2017, which ended September 30, 2016.
First quarter 2017 revenue of $442.2 million increased 5% as reported and increased 7% in constant currency from $423.0 million reported in the first quarter a year ago. All three of the Company’s reporting segments posted constant currency revenue growth for the first quarter, led by a double-digit increase in the Drug Delivery Solutions segment.
First quarter 2017 revenue of $442.2 million increased 5% as reported and increased 7% in constant currency from $423.0 million reported in the first quarter a year ago. All three of the Company’s reporting segments posted constant currency revenue growth for the first quarter, led by a double-digit increase in the Drug Delivery Solutions segment.